The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-09. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
=== Menopausal hot flashes === In 2013, low-dose paroxetine was approved in the US for the treatment of moderate-to-severe vasomotor symptoms such as hot flashes and night sweats associated with menopause. At the low dose used for menopausal hot flashes, side effects are similar to placebo and dose tapering is not required for discontinuation.
Gram-positive organisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis Gram-negative organisms: Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Susceptible bacteria for CABP are: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible [MSSA] isolates only), Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae. It has not been tested in pregnant women. In the European Union, it is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections.
The CDC has also expanded its Get Ahead of Sepsis campaign in 2023, focusing on raising awareness of AMR's role in sepsis and promoting the judicious use of antibiotics in both healthcare and community settings. This initiative has reached millions through social media, healthcare facilities, and public health outreach, aiming to educate the public on the importance of preventing infections and reducing antibiotic misuse. Under the administration of Donald J. Trump, severe federal funding cuts in 2025 at the National Institutes of Health (NIH) and many other research entities in the United States are expected to impede progress in combating antimicrobial resistance. Public health experts believe these budget reductions will adversely affect the development of new antibiotics as well as advances in diagnostics and treatment strategies, thus undermining efforts currently underway to address AMR. The Infectious Diseases Society of America (IDSA) is but one organization that has expressed grave concern regarding the negative consequences of such extreme budget measures on antimicrobial stewardship, and, as a result, on global health security overall.
==== Other sex-hormonal agents ==== Prasterone vaginal (dehydroepiandrosterone; DHEA; Intrarosa; Vaginorm) – androgen (androgen receptor agonist), other actions – atrophic vaginitis, dyspareunia [142] Testosterone propionate (TP; Synandrol; Synerone) – androgen (androgen receptor agonist) – decreased libido [143] Tibolone (Livial) – androgen, estrogen, and progestogen – atrophic vaginitis, dyspareunia, low sexual desire [144] Triptorelin (Arvekap; AY-25650; BIM-21003; BN-52014; CL-118532; Debio-8200; Debio-8206; debio8200; Decapeptyl; Decapeptyl SR; Decapeptyl LP; Diphereline; Gonapeptyl; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptoreline; Tryptorelin; WY-42422) – gonadotropin-releasing hormone (GnRH) receptor agonist – paraphilias [145]
Sources: en.wikipedia.org
=== Applications === The enhanced sensitivity of eSimoa is crucial for early and accurate biomarker detection in clinical diagnostics, facilitating better disease monitoring and management. In drug discovery, the ability to track subtle changes in enzymatic activity aids in the development of more effective pharmaceuticals by providing detailed insights into enzyme inhibition mechanisms.
== Definition == In scientific literature, porous glass is a porous material containing approximately 96% silica, which is produced by an acidic extraction or a combined acidic and alkaline extraction respectively, of phase separated alkali borosilicate glasses, and features a three-dimensional interconnected porous microstructure. For commercially available porous glasses, the terms porous VYCOR-Glass (PVG) and Controlled Pore Glass (CPG) are used. The pore structure is formed by a syndetic channel system and has a specific surface from 10 to 300 m2/g. Porous glasses can be generated by an acidic extraction of phase separated alkaliborosilica glasses, or by a sol-gel-process. By regulating the manufacturing parameters, it is possible to produce a porous glass with a pore size of between 0.4 and 1000 nm in a very narrow pore size distribution. You can generate various moulds, for example, irregular particles (powder, granulate), spheres, plates, sticks, fibers, ultra thin membranes, tubes and rings.
In humans, the total female diploid nuclear genome per cell extends for 6.37 Gigabase pairs (Gbp), is 208.23 cm long and weighs 6.51 picograms (pg). Male values are 6.27 Gbp, 205.00 cm, 6.41 pg. Each DNA polymer can contain hundreds of millions of nucleotides, such as in chromosome 1. Chromosome 1 is the largest human chromosome with approximately 220 million base pairs, and would be 85 mm long if straightened. In eukaryotes, in addition to nuclear DNA, there is also mitochondrial DNA (mtDNA) which encodes certain proteins used by the mitochondria. The mtDNA is usually relatively small in comparison to the nuclear DNA. For example, the human mitochondrial DNA forms closed circular molecules, each of which contains 16,569 DNA base pairs, with each such molecule normally containing a full set of the mitochondrial genes. Each human mitochondrion contains, on average, approximately 5 such mtDNA molecules. Each human cell contains approximately 100 mitochondria, giving a total number of mtDNA molecules per human cell of approximately 500. However, the amount of mitochondria per cell also varies by cell type, and an egg cell can contain 100,000 mitochondria, corresponding to up to 1,500,000 copies of the mitochondrial genome (constituting up to 90% of the DNA of the cell).
Inlet: a substrate (typically cellulose) where liquids are dispensed manually. Channels: hydrophilic sub-millimeter networks that guide liquid throughout a device. Flow amplifiers: regions of varying geometry where the flow velocity is modified to impart a steady state flow of controllable velocity Flow resistors: a capillary element used to impart a reduced flow velocity in order to control the residence time of a fluid in a microfluidic device Barriers: hydrophobic regions that prevent fluid from leaving the channel. Outlets: location where a chemical or biochemical reaction takes place.
On radiographs, the differences in the mineralization of different parts of the tooth and surrounding periodontium can be noted; enamel appears lighter than dentin or pulp since it is denser than both and more radiopaque. Enamel does not contain collagen, as found in other hard tissues such as dentin and bone, but it does contain two unique classes of proteins: amelogenins and enamelins. While the role of these proteins is not fully understood, it is believed that they aid in the development of enamel by serving as a framework for minerals to form on, among other functions. Once it is mature, enamel is almost totally without the softer organic matter. Enamel is avascular and has no nerve supply within it and is not renewed, however, it is not a static tissue as it can undergo mineralization changes.
Sources: en.wikipedia.org
On 3 December, Hezbollah fired two projectiles at the Shebaa Farms in what it described as a "defensive and warning response", accusing Israel of committing repeated ceasefire violations. In response, the IDF conducted a wave of strikes in southern Lebanon, killing nine people. Two people, including a Lebanese security services corporal, were killed by Israeli strikes earlier that day. On 9 December, four reservists of the 35th Paratroopers Brigade were killed in an accident when unmarked munitions exploded in a tunnel in the Labbouneh area, which detonated Hezbollah weaponry, leading to the tunnel's collapse. The IDF withdrew from Al-Khiyam on 12 December in accordance with the ceasefire. On 26 January 2025, a day before the ceasefire's deadline, Israeli forces fired at Lebanese residents en route to communities near the border, killing 22 people and injuring 124. After the ceasefire's initial deadline passed on 27 January, Israeli troops refused to withdraw from southern Lebanon, accusing the Lebanese government of not upholding the deal. The ceasefire was extended to 18 February. On 13 February, the IDF accused Iran's Quds Force of smuggling cash onto civilian flights en route to Beirut–Rafic Hariri International Airport to fund Hezbollah. In response, Lebanon blocked an Iranian passenger plane from entering its territory. The decision sparked protests from Hezbollah supporters, who blocked access to the airport, and on 15 February, attacked a UNIFIL convoy en route to the airport, injuring deputy force commander Chok Bahadur Dhakal.
Medical incubator: a business incubator focused on medical devices and biomaterials This type of business incubator focuses on start-up advice for medical devices and biomaterials. Medical technologies are always changing and improving, and therefore this type of incubator is ideal for encouraging innovation and entrepreneurship within the medical field.
The vaginal environment is slightly acidic, with pH ranging from 3.8 - 4.5 based on multiple factors such as age, natural bacteria, and stage of menstrual cycle. Due to the variety in possible pH values, this poses an interesting consideration for drug delivery. Absorption and release of drugs is often influenced by pH, so if the pH is changing through the menstrual cycle, different combinations could be needed at different times to achieve the most effective drug delivery system.
==== Documentary films ==== Detox or Die (2004). Directed by David Graham Scott. Scott begins videotaping his heroin-addicted friends. Before long, he himself is addicted to the drug. He eventually turns the camera on himself and his family. After 12 years of debilitating, painful dependence on methadone, Scott turns to ibogaine. Filmed in Scotland and England, and broadcast on BBC One as the third installment in the documentary series One Life. Ibogaine: Rite of Passage (2004). Directed by Ben Deloenen. Cy, a 34-year-old heroin addict, undergoes ibogaine treatment with Dr. Martin Polanco at the Ibogaine Association, a clinic in Rosarito, Mexico. Deloenen interviews people formerly addicted to heroin, cocaine, and methamphetamine, who share their perspectives about ibogaine treatment. In Gabon, a Babongo woman receives iboga root for her depressive malaise. Deloenen visually contrasts this Western, clinical use of ibogaine with the Bwiti use of iboga root, but emphasizes the Western context. Facing the Habit (2007). Directed by Magnolia Martin. Martin's subject is a former millionaire and stockbroker who travels to Mexico for ibogaine treatment for heroin addiction. Tripping in Amsterdam (2008). In this short film directed by Jan Bednarz, Simon "Swany" Wan visits Sara Glatt's iboga treatment center in Amsterdam. Current TV broadcast the documentary in 2008 as part of their "Quarter-life Crisis" programming roster. I'm Dangerous with Love (2009). Directed by Michel Negroponte.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.